NCT01957280View on ClinicalTrials.gov

Study to Assess Pharmacokinetics, Immunogenicity and Safety/Tolerability of Patritumab (U3-1287)

PHASE1CompletedINTERVENTIONAL

Enrollment

17

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

October 31, 2013

Study Completion Date

April 30, 2014

Conditions

Solid Tumors

Interventions

DRUG

patritumab

Trial Locations (3)

33612

Tampa

73104

Oklahoma City

78229

San Antonio

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Daiichi Sankyo

INDUSTRY